PMEF
VRCA icon

Point72 Middle East FZE’s Verrica Pharmaceuticals VRCA Stock Holding History

Point72 Middle East FZE’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-320
Closed -$20.8K – 2094
2023
Q1 		$20.8K Buy
+320
New +$19.4K ﹤0.01% 1423

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Point72 Middle East FZE's VRCA Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Verrica Pharmaceuticals (VRCA) in Q2 2023, closing a stake of 320 shares — an estimated $20.8K sold.

Point72 Middle East FZE first reported a position in VRCA in Q1 2023 and held it in 1 quarter. The position peaked at $20.8K in Q1 2023. 63 funds tracked by Wall St. Rank hold VRCA as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Verrica Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 320 Verrica Pharmaceuticals shares in Q2 2023, an estimated $20.8K.
  • Point72 Middle East FZE first reported a position in Verrica Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Verrica Pharmaceuticals position peaked at $20.8K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.